These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26482681)

  • 21. Antidiabetic activity of
    Mohanty IR; Kumar CS; Borde M
    Indian J Pharmacol; 2021; 53(5):384-387. PubMed ID: 34854407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
    Xie W; Song X; Liu Z
    Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches.
    Han R; Maycock J; Murray BS; Boesch C
    Food Res Int; 2019 Jan; 115():283-291. PubMed ID: 30599943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding treatment options for type 2 diabetes: the old and the new.
    Pratley RE
    Diabetes Educ; 2009; 35 Suppl 1():4S-11S. PubMed ID: 19218561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPP-4 inhibitors in the treatment of type 2 diabetes.
    Duez H; Cariou B; Staels B
    Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of the DPP-4 inhibitors.
    Jose T; Inzucchi SE
    Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):525-39. PubMed ID: 16939389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review.
    Liu R; Cheng J; Wu H
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.
    Darsalia V; Larsson M; Klein T; Patrone C
    Cardiovasc Diabetol; 2018 Feb; 17(1):32. PubMed ID: 29466979
    [No Abstract]   [Full Text] [Related]  

  • 37. A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity.
    Chhabria S; Mathur S; Vadakan S; Sahoo DK; Mishra P; Paital B
    Front Endocrinol (Lausanne); 2022; 13():1027237. PubMed ID: 36440220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Hypoglycemic Activities of
    Cheng Z; Chen J; Zhang Y; Li X; Zhang N; Liu F; Jiao Y
    Foods; 2024 Feb; 13(4):. PubMed ID: 38397496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.